AGT and cardiac hypertrophy: Although the hypotensive action of B38-CAP is mediated mainly through Ang II downregulation, B38-CAP (2 ~ 3 mg kg−1 per day) exhibits a more potent therapeutic effect in TAC-induced heart failure than in Ang II-induced heart failure (e.g., 87.9% inhibition of cardiac hypertrophy (HW/BW increase) in TAC model vs. 53.2% inhibition in Ang II-infusion model).